News Related to AIM ImmunoTech Inc.

Related coverage linked through entity extraction aliases.

Three Cancer Drug Trials Advance: AIM Plans Phase 3, Innovent Doses First Patient

Mar 02, 2026

AIM ImmunoTech partners with Thermo Fisher to design Phase 3 trial for Ampligen in pancreatic cancer, while Innovent Biologics begins dosing patients in Phase 3 study of IBI354 for HER2-positive breast cancer.

AIM ImmunoTech Announces Phase 2 Ampligen Trial Milestones for Pancreatic Cancer

Feb 24, 2026

AIM ImmunoTech outlined key milestones for its Phase 2 DURIPANC trial evaluating Ampligen combined with durvalumab in metastatic pancreatic cancer, with primary endpoint evaluation expected in December 2026.